Quotes 5-day view Delayed Swiss Exchange
09/14/2020
09/15/2020
09/16/2020
09/17/2020
09/18/2020
Date
81.9(c)
83.06(c)
82.27(c)
82.3(c)
82.93(c)
Last
4 772 060
6 300 748
9 241 833
6 353 354
12 398 131
Volume
+0.12% +1.42% -0.95% +0.04% +0.77% Change
Sales 2020
49 760 M - -
Net income 2020
8 967 M - -
Net Debt 2020
18 028 M - -
P/E ratio 2020
22,6x
Yield 2020
3,47%
Sales 2021
52 836 M - -
Net income 2021
10 442 M - -
Net Debt 2021
12 968 M - -
P/E ratio 2021
19,4x
Yield 2021
3,59%
Capitalization
200 B 201 B -
EV / Sales 2020
4,39x
EV / Sales 2021
4,04x
Nbr of Employees
110 000
Free-Float
86,9%
Novartis is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical products (79.5%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal disorders, cancers, central nervous system disorders, hormone imbalances, etc.;
- generic drugs (20.5%; Sandoz).
Net sales...
Notations Surperformance© of Novartis AG
Trading Rating : Investor Rating :
All news about NOVARTIS AG
News in other languages on NOVARTIS AG
Analyst Recommendations on NOVARTIS AG
NOVARTIS AG
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends NOVARTIS AG
Short Term Mid-Term Long Term Trends Bullish Neutral Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
22
Average target price
107,12 $
Last Close Price
90,92 $
Spread / Highest target
42,5%
Spread / Average Target
17,8%
Spread / Lowest Target
-10,4%
Please enable JavaScript in your browser's settings to use dynamic charts.
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
